Improvement of immunogenic chemotherapy by STAT3 inhibition. (1st February 2016)

• Record Type: Journal Article
• Authors: Yang, Heng; Yamazaki, Takahiro; Pietrocola, Federico; Zhou, Heng; Zitvogel, Laurence; Ma, Yuting; Kroemer, Guido
• Is Part Of: Oncoimmunology. Volume 5:Number 2(2016)
• Publication Date: 2016-02-01
• Subjects: Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2015.1078061
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: The inhibition of STAT3 may exert cell-autonomous cytotoxic and cytostatic effects, yet may also stimulate anticancer immunosurveillance through the neutralization of immunosuppressive circuitries. In addition, STAT3 inhibition in cancer cells may stimulate the type 1 interferon response elicited by anthracyclines. This pathway results in an enhanced chemotherapy-associated anticancer immune response with improved therapeutic efficacy. Hence, combination therapies that include immunogenic cell death (ICD) inducers and STAT3 inhibitors can be envisaged.